CN101977606A - 使用nmda nr2b亚型选择性拮抗剂来治疗病症的方法 - Google Patents

使用nmda nr2b亚型选择性拮抗剂来治疗病症的方法 Download PDF

Info

Publication number
CN101977606A
CN101977606A CN2009801104274A CN200980110427A CN101977606A CN 101977606 A CN101977606 A CN 101977606A CN 2009801104274 A CN2009801104274 A CN 2009801104274A CN 200980110427 A CN200980110427 A CN 200980110427A CN 101977606 A CN101977606 A CN 101977606A
Authority
CN
China
Prior art keywords
compound
pain
formula
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801104274A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·A·肯普
蒂莫西·塔斯克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec Neurosciences GmbH
Original Assignee
Evotec Neurosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences GmbH filed Critical Evotec Neurosciences GmbH
Publication of CN101977606A publication Critical patent/CN101977606A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801104274A 2008-03-27 2009-03-26 使用nmda nr2b亚型选择性拮抗剂来治疗病症的方法 Pending CN101977606A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4008708P 2008-03-27 2008-03-27
US61/040,087 2008-03-27
PCT/EP2009/002241 WO2009118187A1 (en) 2008-03-27 2009-03-26 Methods for treating disorders using nmda nr2b-subtype selective antagonist

Publications (1)

Publication Number Publication Date
CN101977606A true CN101977606A (zh) 2011-02-16

Family

ID=40910288

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801104274A Pending CN101977606A (zh) 2008-03-27 2009-03-26 使用nmda nr2b亚型选择性拮抗剂来治疗病症的方法

Country Status (14)

Country Link
US (1) US20110053951A1 (https=)
EP (1) EP2254580A1 (https=)
JP (3) JP2011516417A (https=)
KR (1) KR20100135847A (https=)
CN (1) CN101977606A (https=)
AU (1) AU2009228660B2 (https=)
BR (1) BRPI0909378A2 (https=)
CA (1) CA2719749A1 (https=)
IL (1) IL207835A0 (https=)
MX (1) MX2010009649A (https=)
NZ (1) NZ588698A (https=)
RU (1) RU2499598C2 (https=)
WO (1) WO2009118187A1 (https=)
ZA (1) ZA201006587B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071488A (zh) * 2016-02-10 2018-12-21 詹森药业有限公司 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013251079B2 (en) 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
WO2015175806A1 (en) * 2014-05-16 2015-11-19 The Trustees Of The University Of Pennsylvania Applications of automatic anatomy recognition in medical tomographic imagery based on fuzzy anatomy models
ES2791252T3 (es) * 2014-08-15 2020-11-03 Janssen Pharmaceuticals Inc Pirazoles
WO2016025917A1 (en) * 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
BR112017025023B1 (pt) 2015-06-01 2024-01-30 Rugen Holdings (Cayman) Limited Compostos heterocíclicos de carbamato de 3,3-difluoropiperidina, seu uso como antagonistas do receptor nmda nr2b e composição farmacêutica que os compreende
HRP20200410T1 (hr) 2015-07-09 2020-08-21 Janssen Pharmaceutica Nv Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
US10732235B2 (en) * 2018-03-29 2020-08-04 Siemens Healthcare Gmbh Magnetic resonance method and apparatus using atlas-based masking for quantitative susceptibility mapping
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
KR20220024403A (ko) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
CN113950357A (zh) 2019-06-14 2022-01-18 詹森药业有限公司 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途
SG11202112405VA (en) 2019-06-14 2021-12-30 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
CN113993868A (zh) 2019-06-14 2022-01-28 詹森药业有限公司 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
AU2020293642A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT885004E (pt) * 1996-03-08 2002-08-30 Hoffmann La Roche Utilizacao de derivados de 4-fenil-3,6-di-hidro-2h-piridilo como bloqueadores dos subtipos dos receptores nmda
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
EP1070708B1 (en) * 1999-07-21 2004-01-14 F. Hoffmann-La Roche Ag Triazole derivatives
ES2225553T3 (es) * 2000-04-20 2005-03-16 F. Hoffmann-La Roche Ag Derivados de pirrolidina y piperidina y su empleo para el tratamiento de trastornos neurodegenerativos.
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
AU2001296994A1 (en) * 2000-10-06 2002-04-15 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CA2617104A1 (en) * 2005-07-29 2007-02-08 Regents Of The University Of Minnesota Amyloid beta receptor and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071488A (zh) * 2016-02-10 2018-12-21 詹森药业有限公司 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂
CN109071488B (zh) * 2016-02-10 2021-08-13 詹森药业有限公司 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂

Also Published As

Publication number Publication date
JP2016094430A (ja) 2016-05-26
KR20100135847A (ko) 2010-12-27
IL207835A0 (en) 2010-12-30
WO2009118187A1 (en) 2009-10-01
JP2011516417A (ja) 2011-05-26
CA2719749A1 (en) 2009-10-01
RU2010143864A (ru) 2012-05-10
BRPI0909378A2 (pt) 2015-10-06
NZ588698A (en) 2012-06-29
AU2009228660A1 (en) 2009-10-01
MX2010009649A (es) 2010-12-17
AU2009228660B2 (en) 2012-11-29
ZA201006587B (en) 2012-02-29
US20110053951A1 (en) 2011-03-03
JP2014098018A (ja) 2014-05-29
RU2499598C2 (ru) 2013-11-27
EP2254580A1 (en) 2010-12-01

Similar Documents

Publication Publication Date Title
CN101977606A (zh) 使用nmda nr2b亚型选择性拮抗剂来治疗病症的方法
Li et al. Craving correlates with mesolimbic responses to heroin-related cues in short-term abstinence from heroin: an event-related fMRI study
Mitchell et al. Good night and good luck: norepinephrine in sleep pharmacology
Vernon et al. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation
Pertovaara et al. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective α2‐adrenoceptor antagonist
Murrough et al. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder
Furmark et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo
Yamanaka et al. A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques
Fukumoto et al. Medial PFC AMPA receptor and BDNF signaling are required for the rapid and sustained antidepressant-like effects of 5-HT1A receptor stimulation
Okita et al. Emotion dysregulation and amygdala dopamine D2-type receptor availability in methamphetamine users
Paasonen et al. Comparison of seven different anesthesia protocols for nicotine pharmacologic magnetic resonance imaging in rat
Müller et al. The in vivo neurochemistry of the brain during general anesthesia
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
Di Ianni et al. Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats
Spagnolo et al. Striatal dopamine release in response to morphine: a [11C] raclopride positron emission tomography study in healthy men
Alkislar et al. Inhaled cannabis suppresses chemotherapy-induced neuropathic nociception by decoupling the raphe nucleus: a functional imaging study in rats
TW202227087A (zh) 精神分裂症之治療
Chin et al. Pharmacological MRI in awake rats reveals neural activity in area postrema and nucleus tractus solitarius: relevance as a potential biomarker for detecting drug-induced emesis
JP2009521403A (ja) Ｍｒｉによる神経発生の相関の画像法
US20230270693A1 (en) Molecular Targets for Modulation of Dissociative and Associative States
Littlewood et al. Using the BOLD MR signal to differentiate the stereoisomers of ketamine in the rat
CA2304592A1 (en) Inhibition of psychostimulant-induced and nicotine-induced craving
Müller Herde et al. Chronic nicotine exposure alters metabotropic glutamate receptor 5: longitudinal PET study and behavioural assessment in rats
Akbari et al. Injection of resistin into the paraventricular nucleus produces a cardiovascular response that may be mediated by glutamatergic transmission in the rostral ventrolateral medulla
Min et al. Positive feedback role of TRPC3 in TNF-α-mediated vasogenic edema formation induced by status epilepticus independent of ETB receptor activation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: hamburg

Applicant after: Evotec Neurosciences GmbH

Address before: hamburg

Applicant before: Evotec Neurosciences GmbH

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: EVOTEC NEUROSCIENCES GMBH TO: EVOTEC INTERNATIONAL GMBH

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110216